Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E. Vitolo U, et al. Among authors: sarris ah. J Clin Oncol. 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646602 Free article. Clinical Trial.
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.
Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thiéblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK; International Extranodal Lymphoma Study Group. Zucca E, et al. Among authors: sarris ah. J Clin Oncol. 2003 Jan 1;21(1):20-7. doi: 10.1200/JCO.2003.11.141. J Clin Oncol. 2003. PMID: 12506165
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11).
Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortelazzo S. Mian M, et al. Among authors: sarris ah. Ann Hematol. 2011 Apr;90(4):401-8. doi: 10.1007/s00277-010-1083-1. Epub 2010 Sep 25. Ann Hematol. 2011. PMID: 20872000
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. Romaguera JE, et al. Among authors: sarris ah. J Clin Oncol. 2005 Oct 1;23(28):7013-23. doi: 10.1200/JCO.2005.01.1825. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145068 Clinical Trial.
Trimetrexate in relapsed T-cell lymphoma with skin involvement.
Sarris AH, Phan A, Duvic M, Romaguera J, McLaughlin P, Mesina O, King K, Medeiros LJ, Rassidakis GZ, Samuels B, Cabanillas F. Sarris AH, et al. J Clin Oncol. 2002 Jun 15;20(12):2876-80. doi: 10.1200/JCO.2002.08.006. J Clin Oncol. 2002. PMID: 12065565 Clinical Trial.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Goy A, et al. Among authors: sarris ah. J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613697 Clinical Trial.
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.
Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Chronowski GM, et al. Among authors: sarris ah. Am J Clin Oncol. 2004 Feb;27(1):73-80. doi: 10.1097/01.coc.0000045853.73233.42. Am J Clin Oncol. 2004. PMID: 14758137
115 results